Ravichandran Rao
Director/Board Member at TRex Bio Ltd.
Profile
PresentRavi has been a strategic leader in the research, development, manufacturing, or commercialization activities of 5 approved drugs (FASENRA®, LUMOXITI®, ONIVYDE®, KEYTRUDA®, and CYTOGAM®) and two biology discovery platforms (ATLAS™ Platform and TRex Discovery Platform).
He is a company builder and has served as CEO of early-stage bio companies.
Ravi served as the CEO of TRex Bio, where he conceptualized and built a company aimed at discovering new therapies to restore tissue homeostasis.
Before that, he served as the interim CEO of Complexa, leading the turnaround of the organization.
Before Complexa, as the Chief Business Officer of Vtesse, he played a critical cross-functional role in corporate strategy, product development, and financial operations, leading the company from Phase I to a fully enrolled global Phase III within 18 months.
He was instrumental in the sale of the company after the enrollment of Phase III.
Before Vtesse, he held increasing levels of responsibilities within corporate development and strategy consulting at Merrimack Pharmaceuticals, Genocea Biosciences, MedImmune/AstraZeneca, and Booz&Co. While at MedImmune, Ravi built the immunology product portfolio de novo as well as the crafting the journeys of several drugs, including FASENRA®, LUMOXITI®, DAXDILIMAB, and CYTOGAM®.
Ravi holds a B.S.
in Biology and Chemistry from the University of Wisconsin and a Ph.D.
in Biochemistry and Molecular Biophysics from the University of Pennsylvania.
Ravichandran Rao active positions
| Companies | Position | Start |
|---|---|---|
TRex Bio Ltd.
 TRex Bio Ltd. BiotechnologyHealth Technology TRex Bio Ltd. is a British company that provides biotechnology research and development services. The private company is based in London, UK. The company was founded in 2018 by Houman Ashrafian. | Director/Board Member | 2018-11-11 |
Samsara Biocapital LLC
 Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | Private Equity Investor | 2021-12-31 |
Former positions of Ravichandran Rao
| Companies | Position | End |
|---|---|---|
Trex Bio, Inc.
 Trex Bio, Inc. Pharmaceuticals: MajorHealth Technology Trex Bio, Inc. manufactures immunotherapies for autoimmune and inflammatory diseases. The company is headquartered in South San Francisco, CA. | Chief Executive Officer | 2020-12-31 |
Complexa, Inc.
 Complexa, Inc. Pharmaceuticals: MajorHealth Technology Complexa, Inc. operates as a biopharmaceutical company which engages on discovering and developing therapies for the treatment of severe and life-threatening fibrosis and inflammatory diseases. The firm focuses on two therapeutic areas: focal segmental glomerulosclerosis (FSGS) and pulmonary arterial hypertension (PAH), two rare diseases that can compromise the normal function of the kidney and the heart. The company was founded by Bruce A. Freeman, Raymond A. Miller, and Margaret M. Tarpey in 2008 and is headquartered in Berwyn, PA. | Chief Executive Officer | 2017-12-31 |
Vtesse, Inc.
 Vtesse, Inc. BiotechnologyHealth Technology Vtesse, Inc. provides novel drugs for life-threatening rare diseases. It developed VTS-270, a modified form of cyclodextrin that has been evaluated in preclinical and clinical studies at institutes within the National Institutes of Health (NIH) to treat patients with Niemann-Pick Disease Type C (NPC). The firm is working with the NIH and other leading academic centers to advance clinical study of VTS-270 for NPC, and to conduct pre-clinical discovery and development of other novel drugs for NPC and other LSDs. The company was founded by Ben Machielse in 2015 and is headquartered in Gaithersburg, MD. | Corporate Officer/Principal | 2016-12-31 |
| GENOCEA BIOSCIENCES, INC. | Private Equity Investor | 2013-12-31 |
MedImmune LLC
 MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Director/Board Member | 2010-12-31 |
Training of Ravichandran Rao
| University of Pennsylvania | Doctorate Degree |
| University of Wisconsin Superior | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| GENOCEA BIOSCIENCES, INC. | Health Technology |
| Private companies | 7 |
|---|---|
MedImmune LLC
MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Health Technology |
Complexa, Inc.
Complexa, Inc. Pharmaceuticals: MajorHealth Technology Complexa, Inc. operates as a biopharmaceutical company which engages on discovering and developing therapies for the treatment of severe and life-threatening fibrosis and inflammatory diseases. The firm focuses on two therapeutic areas: focal segmental glomerulosclerosis (FSGS) and pulmonary arterial hypertension (PAH), two rare diseases that can compromise the normal function of the kidney and the heart. The company was founded by Bruce A. Freeman, Raymond A. Miller, and Margaret M. Tarpey in 2008 and is headquartered in Berwyn, PA. | Health Technology |
Vtesse, Inc.
Vtesse, Inc. BiotechnologyHealth Technology Vtesse, Inc. provides novel drugs for life-threatening rare diseases. It developed VTS-270, a modified form of cyclodextrin that has been evaluated in preclinical and clinical studies at institutes within the National Institutes of Health (NIH) to treat patients with Niemann-Pick Disease Type C (NPC). The firm is working with the NIH and other leading academic centers to advance clinical study of VTS-270 for NPC, and to conduct pre-clinical discovery and development of other novel drugs for NPC and other LSDs. The company was founded by Ben Machielse in 2015 and is headquartered in Gaithersburg, MD. | Health Technology |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | Finance |
Merrimack Ales LLC
 Merrimack Ales LLC Beverages: AlcoholicConsumer Non-Durables Merrimack Ales LLC is engaged in brewery production. It includes perennials, seasonal, and hypothesis beer. The company was founded by Adam Pearson in 2014 and is headquartered in Lowell, MA. | Consumer Non-Durables |
Trex Bio, Inc.
Trex Bio, Inc. Pharmaceuticals: MajorHealth Technology Trex Bio, Inc. manufactures immunotherapies for autoimmune and inflammatory diseases. The company is headquartered in South San Francisco, CA. | Health Technology |
TRex Bio Ltd.
TRex Bio Ltd. BiotechnologyHealth Technology TRex Bio Ltd. is a British company that provides biotechnology research and development services. The private company is based in London, UK. The company was founded in 2018 by Houman Ashrafian. | Health Technology |
- Stock Market
- Insiders
- Ravichandran Rao